Please login to the form below
No cardiovascular risk found in Prilosec/ Nexium says FDA
The FDA's review of clinical studies involving AstraZeneca's antacid drugs Nexium and Prilosec does not demonstrate an increase in heart attacks and sudden death
The FDA's review of clinical studies involving UK-headquartered AstraZeneca's (AZ) antacid drug Nexium (esomeprazole) and Prilosec (omeprazole) has not demonstrated an increase in heart attacks and sudden death.
Since May 2007, the FDA has been conducting a safety review of the drugs, which are approved to treat gastroesophageal reflux disease, when AZ submitted the results of two small, long-term studies that suggested the drug could increase the risk of heart problems and sudden death. Prilosec is also marketed in OTC versions in the US.
The FDA asked AZ to submit extra data about the drugs for review. The agency said its review of the two long-term studies, along with 14 additional studies, shows the products are "not likely to be associated with an increased risk of heart problems".
Share
Related Hub content
Featured jobs
- Business Development Director – Health Education
-
excellent commission
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Systematic Reviewer - Oxford
-
Negotiable
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Account Manager / Account Director
-
Competative
-
Account Director
-
Competitive Salary Offered
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Experienced Medical Writers
-
Competitive Salary and Benefits
-
Associate Director
-
£75, 000-90, 000
- Account Manager- Healthcare Advertising
-
Negotiable
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Account Manager- Healthcare Advertising
-
Negotiable
Subscribe to our email news alerts
- Report: Achieving launch excellence in the challenging healthcare markets of today
- What is blockchain and why should i care - Richard Springham
- NHS medicines optimisation milestone
- AZ and CRUK launch Cambridge genomics centre
- eConsent: Busting regulatory myths
- New Pfizer UK leader as Nordkamp moves into European role
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
